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Fabry disease patients show a deficiency in the
activity of the lysosomal enzyme a-galactosidase
(a-GAL or a-Gal A). One proposed treatment for
Fabry disease is pharmacological chaperone
therapy, where a small molecule stabilizes the
a-GAL protein, leading to increased enzymatic
activity. Using enzyme kinetics, tryptophan fluores-
cence, circular dichroism, and proteolysis assays,
we show that the pharmacological chaperones
1-deoxygalactonojirimycin (DGJ) and galactose
stabilize the human a-GAL glycoprotein. Crystal
structures of complexes of a-GAL and chaperones
explain the molecular basis for the higher potency
of DGJ over galactose. Using site-directed mutagen-
esis, we show the higher potency of DGJ results from
an ionic interaction with D170. We propose that
protonation of D170 in acidic conditions leads to
weaker binding of DGJ. The results establish
a biochemical basis for pharmacological chaperone
therapy applicable to other protein misfolding
diseases.
INTRODUCTION
a-Galactosidase (a-GAL, also known as a-galactosidase A or
a-GAL A; Enzyme Commission number 3.2.1.22) is a lysosomal
glycosidase that breaks down complex macromolecules for
cellular reuse. a-GAL catalyzes the hydrolysis of terminal
a-linked galactosides from macromolecules. In humans, defi-
ciency of the a-GAL enzyme causes Fabry disease, a lysosomal
storage disease characterized by the progressive accumulation
ofmetabolites in the cells, leading to tissue damage and eventual
organ failure (Brady et al., 1967; Desnick et al., 2001). Many
Fabry disease-causing mutations have been identified in the
GLA gene encoding the a-GAL protein (Human Gene Mutation
Database, http://www.hgmd.org), most of which disrupt the
hydrophobic core of the protein, presumably leading to protein
misfolding and degradation in the endoplasmic reticulum (ER)
(Eng and Desnick, 1994; Fan et al., 1999; Garman and Garboczi,
2002, 2004; Okumiya et al., 1995; Romeo et al., 1975). Thus,
Fabry disease is primarily a protein misfolding disease.Chemistry & Biology 18, 1521–152The only currently approved treatment for Fabry disease is
enzyme replacement therapy (ERT), where recombinant enzyme
is intravenously administered into patients to restore the missing
enzymatic function. ERT has demonstrated reduction of accu-
mulated substrate in tissues, leading to clinical improvement of
Fabry disease patients (Eng et al., 2001; Schiffmann et al.,
2001), and has been proposed for many inherited metabolic
diseases (Beutler, 2006).
An alternative treatment, pharmacological chaperone (PC)
therapy, has been proposed for Fabry disease and other protein
misfolding diseases (Fan and Ishii, 2007; Parenti, 2009; Sawkar
et al., 2005; Suzuki et al., 2009; Tan et al., 1991). In contrast to
using nonspecific small molecules for ‘‘chemical chaperone
therapy,’’ PC therapy for Fabry disease uses an active-site-
specific chaperone, such as the catalytic product galactose
(Frustaci et al., 2001), or a product analog, such as the imino
sugar 1-deoxygalactonojirimycin (DGJ, currently in phase III
clinical trials) (Asano et al., 2000). In PC therapy, the small
molecule is hypothesized to stabilize the folded enzyme, shifting
the folding equilibrium toward properly folded protein, and
reducing removal of the polypeptide through ER-associated
degradation (ERAD) (Cohen and Kelly, 2003; Fan et al., 1999;
Yam et al., 2006; Yam et al., 2005). PCs such as DGJ and galac-
tose are promising clinical candidates, but their biochemical
mechanism is not well understood; they have been proposed
to accelerate the folding of their target, to slow the unfolding of
the target, to stabilize the target, to allow for proper folding, to
promote posttranslational modification, and/or to allow binding
of a partner to the target (Fan et al., 1998; Lieberman et al.,
2009). Additionally, how competitive enzymatic inhibition leads
to increased activity remains unresolved. Because of their
potential for treating a wide range of protein misfolding diseases
(Cohen and Kelly, 2003), PCs have attracted intense clinical
attention.
In this study, we examined the biochemical and biophysical
basis for PC binding to human a-GAL. We showed via biochem-
ical assays that DGJ binds to and stabilizes a-GAL with higher
potency than galactose. We investigated the effect of pH on
the binding affinities of DGJ and galactose and showed that
the chaperones stabilize a-GAL better at near-neutral pH than
at acidic pH. Crystal structures of a-GAL in complex with the
PCs DGJ and galactose revealed a key ionic interaction critical
for the increased potency of DGJ. Finally, we performed
biochemical studies on a D170A variant of a-GAL, unambigu-
ously identifying the atomic interaction responsible for the
increased potency of DGJ over galactose.6, December 23, 2011 ª2011 Elsevier Ltd All rights reserved 1521
Figure 1. Pharmacological Chaperones Slow the Unfolding Kinetics
of a-GAL (Measured by Trp Fluorescence)
(A–D) Unfolding of a-GAL at pH 6.5 (A and B) and pH 4.5 (C and D) in the
absence (open symbols) and presence (filled symbols) of 50 mMDGJ (A and C)
and 50 mM galactose (B and D). See also Figure S2.
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Binding of Pharmacological Chaperones
Tomeasure binding of the PCsDGJ and galactose, we examined
the enzymatic activity of a-GAL in the presence of the chaper-
ones. Both DGJ and galactose act as competitive inhibitors
of a-GAL. We determined the Ki for DGJ to be 39 nM and
for galactose to be 16 mM (Figure S1; Table S1 available
online). The enzymatic assays showed that DGJ is 400,000-
fold more potent than galactose at inhibiting a-GAL, corre-
sponding to 7.6 kcal/mol of additional binding energy, a remark-
able difference for molecules that differ in only two functional
groups.
Resistance to Unfolding Monitored by Trp Fluorescence
To measure the unfolding rate of a-GAL in 7.5 M urea, we used
intrinsic tryptophan fluorescence. The fluorescence signal of
a-GAL shows a decrease in fluorescence intensity and a red
shift in lmax from 335 nm to 350 nm as the protein denatures.
In the absence of chaperone, a-GAL denatures with a t½ of
2.2 hr at pH 6.5 and 1.3 hr at pH 4.5 (Figures 1 and S2), indicating
that a-GAL chemically denatures slightly faster at a lower pH.
Next, to test the effect of DGJ on the unfolding rate, we
repeated the fluorescence assay after preincubation with
DGJ. The rate of unfolding of a-GAL is slowed considerably
by the addition of PCs, particularly at pH 6.5. At pH 6.5, the
addition of 50 mM DGJ slows the unfolding of a-GAL to a t½
greater than 24 hr, with little change in the fluorescence
spectrum over 24 hr. At pH 4.5, the addition of 50 mM DGJ
decreases the rate of unfolding of a-GAL from a t½ of 1.3 hr to
6.5 hr.
Third, to test the effect of galactose, we repeated the fluores-
cence assay. The addition of 50 mM galactose also slows the
urea unfolding of a-GAL, increasing the t½ of unfolding from
2.2 hr to 8.0 hr at pH 6.5 and from 1.3 hr to 2.5 hr at pH 4.5.
We conclude from these experiments that (1) PCs are able to
slow the rate of unfolding of a-GAL, (2) DGJ is more potent than
galactose at preventing unfolding of a-GAL, and (3) both chaper-
ones slow the unfolding more at pH 6.5 than pH 4.5.
Increase in Apparent Melting Temperature
of a-GAL Measured by Circular Dichroism
To examine the thermal stability of a-GAL, we measured the
apparent melting temperature Tm(app) of a-GAL using the
circular dichroism (CD) signal at 222 nm in thermal denaturation
experiments. To investigate the effects of the PCs DGJ and
galactose and of pH on the stability of a-GAL, we repeated the
thermal denaturations in the presence of the chaperones and
at three pH values. Upon the addition of 50 mMDGJ, the Tm(app)
of a-GAL increases by 13.2C to 22.0C, depending on the pH
(Figure 2; Table S2). In contrast, 50 mM galactose has no effect
on the Tm(app) of a-GAL. However, upon increasing the concen-
tration of galactose 1,000-fold to 50 mM, the Tm(app) of a-GAL
increases by 5.3C to 8.5C.
We also compared the Tm(app) as a function of pH. In the
absence of pharmacological chaperone, the Tm(app) of a-GAL
is unchanged between pH 4.5 and 6.5 (60.7C and 60.8C,
respectively) but is lower at pH 7.2 (56.1C), indicating that the
protein is less stable at higher pH values.1522 Chemistry & Biology 18, 1521–1526, December 23, 2011 ª2011Resistance to Protease Digestion Monitored
by Proteolysis
To examine the effect of the PCs on the resistance of a-GAL to
protease digestion, we performed proteolysis experiments. In
the presence of a protease and urea, the amount of undigested
a-GAL protein represents a measure of the protein’s stability.
To measure the effect of chaperones at pH 6.5, we digested
a-GAL with thermolysin at pH 6.5 and quantitated the amount
of a-GAL resistant to the protease. In the presence of DGJ,
a-GAL becomes increasingly resistant to thermolysin digestion
starting at 500 nM DGJ (Figures 3 and S3). In the presence of
galactose, a-GAL becomes resistant to protease digestion start-
ing at 10,000-fold higher concentration, approximately 5 mM
galactose.
To examine the effect at pH 4.5, we digested a-GAL with
pepsin and quantitated the undigested a-GAL. In the presence
of DGJ, a-GAL becomes increasingly resistant to protease
starting at 500 nM DGJ (Figure 3). In the presence of galactose,
a-GAL becomes resistant to protease starting at 10,000-fold
higher concentration, approximately 5 mM galactose.
The proteolysis experiments mirror the results of the fluores-
cence and CD experiments, showing that both DGJ and galac-
tose are able to stabilize the a-GAL protein. In all three assays,
the potency of DGJ is much higher than galactose. In general,
the stabilizing effects of DGJ are more pronounced at near-
neutral pH.
Structural Basis for Improved Potency of DGJ
To examine the structural effects of PC binding to a-GAL, we
determined high-resolution crystal structures of two complexes:
the a-GAL:DGJ complex at 2.1 A˚ resolution and theElsevier Ltd All rights reserved
Figure 2. Increased Apparent Melting Tempera-
ture Tm(app) of a-GAL (Monitored by CD)
(A–F) DGJ (A, C, and E) and galactose (B, D, and F) were
tested at pH 7.2 (A and B), pH 6.5 (C and D), and pH 4.5
(E and F) in the absence (white symbols) and presence of
50 mM (red symbols) or 50 mM (blue symbols) DGJ or
galactose. In (C) and (E), the D170A mutant is also shown
in the absence (black symbols) and presence (green
symbols) of 1.4 or 2 mM DGJ. The D170A mutant does
not respond to even 30- or 40-fold higher concentrations
of DGJ. See also Table S2.
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examine the atomic basis for the differences in potency between
the chaperones.
The crystal structures show that both DGJ and galactose bind
similarly in the active site of a-GAL, as expected for binding of
a catalytic product and a product analog (Figure 4). There is
a more favorable interaction between D170 and the DGJ ligand
compared to the galactose ligand. In order to act as a nucleophile
in the a-GAL reaction mechanism (Guce et al., 2010), the D170
side chain must be deprotonated and negatively charged. The
DGJ ligand contains a protonatable heterocyclic nitrogen
atom, allowing for an energetically favorable hydrogen bond.
Because the pKa of DGJ is 7.1 (Legler and Pohl, 1986), the
nitrogen is likely protonated in the pH 5.1 crystals, leading to
a highly favorable charged interaction between the DGJ and
the D170 side chain. Galactose functions as a chaperone by
mirroring the binding of the galactoside substrate, and the Ki
for the PC is close to the KM for substrate (5–20 mM). The galac-
tose ligand contains an unprotonated heterocyclic oxygen,Chemistry & Biology 18, 1521–1526, December 23,whichmakes either weak van derWaals interac-
tion with the deprotonated D170 side chain, or
a hydrogen bond if D170 is protonated.
Effect of D170 on the Interaction
with Chaperones
The crystal structures of the complexes of
a-GAL with DGJ and galactose led us to hy-
pothesize that the higher potency of DGJ
derives mainly from an interaction between the
heterocyclic nitrogen of the ligand and the
carboxylate of the catalytic nucleophile D170.
To test this hypothesis, we made a D170A
variant of human a-GAL (lacking the carbox-
ylate) and examined the ability of DGJ to bind
and stabilize this variant. Because the D170A
variant lacks enzymatic activity, we used
biochemical and crystallographic assays to
test PC binding.
First, we repeated the CD thermal denatur-
ation experiments at pH 6.5 and pH 4.5 with
the D170A a-GAL variant. Consistent with our
hypothesis, the D170A a-GAL showed no
increase in Tm(app), even in the presence of
1.4 or 2 mM DGJ (Figure 2), whereas the wild-
type (WT) a-GAL showed a 13C to 21C
increase in Tm(app) with 30- or 40-fold less DGJ. Thus, the
D170 carboxyl is critical to the stabilizing effect of DGJ.
Second, we repeated the proteolysis experiments on the
D170A mutant with DGJ and galactose. In contrast to WT
a-GAL, the D170A variant requires a much higher concentration
of DGJ to protect from digestion. The removal of the D170
carboxylate group increases the DGJ concentration threshold
for protection by over 1,000-fold (Figure 3, S3, and S4). Thus,
the D170 carboxylate group is primarily responsible for the
much higher potency of DGJ. Using galactose as a PC in the
protease assay shows that in the D170A variant, DGJ is no better
than galactose as a PC, with protection occurring at millimolar
concentrations of galactose. These results indicate that the
D170 carboxylate is more critical to the DGJ interaction than it
is to the galactose interaction, and that the increased potency
of DGJ is entirely due to interaction with the D170 side chain.
Third, we determined a crystal structure of DGJ bound to
the D170A mutant a-GAL, which showed that DGJ binds to the
D170A active site identically to WT a-GAL (Figure 4). Thus,2011 ª2011 Elsevier Ltd All rights reserved 1523
Figure 3. DGJ and Galactose Confer Protease
Resistance upon a-GAL
(A and B) Thermolysin (A) and pepsin (B) digestion of WT
a-GAL (open symbols) and D170A a-GAL (filled symbols)
in urea after incubation with DGJ (black lines) and
galactose (gray lines), respectively. WT and D170A a-GAL
band intensities were quantitated at multiple chaperone
concentrations. The D170A mutant responds only to
high concentrations of chaperone. See also Figures S3
and S4.
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tion with the D170 side chain.
Conclusions
Our study shows that PC binding confers thermodynamic
stability to a-GAL and dramatically slows the unfolding of the
protein. In the equilibrium between native and unfolded states
of a-GAL, PC binding to the native state slows the rate of unfold-
ing and shifts the equilibrium toward the native state. This prop-
erty is particularly valuable in the ER, where the folding of the
nascent polypeptide helps it to avoid the ERAD pathway. Stabi-
lization of the native state of the protein increases the fraction of
enzyme that traffics out of the ER and travels to the lysosome.
For a small molecule to be an effective PC, it must be able to
selectively bind to the active site of an enzyme but then disso-
ciate, allowing the enzyme to turnover substrate (Fan, 2003,
2008). Different models exist for the force driving low pH disso-
ciation, including protonation of the PC, protonation of an active
site residue, competition by excess substrate, etc. (Fan, 2003,
2008; Fantur et al., 2010; Jo et al., 2010; Suzuki et al., 2009).
For lysosomal enzymes, the pH dependence of affinity of the1524 Chemistry & Biology 18, 1521–1526, December 23, 2011 ª2011 Elsevier Ltd All rPC is important, as the chaperone must disso-
ciate from the active site at low pH for the
enzyme to function. The heterocyclic nitrogen
of DGJ has a pKa of 7.1, and the protonationstate of PCs has been hypothesized to cause the pH-dependent
release (Fantur et al., 2010). We propose an alternative hypoth-
esis for the pH dependence of DGJ binding to a-GAL: that
the protonation state of the active site nucleophile D170
causes pH dependence. At pH 6.5 and pH 7.2, the D170 carbox-
ylate is expected to deprotonate and the DGJ nitrogen to
protonate, leading to a highly favorable ionic interaction between
them. In contrast, at pH 4.5, the carboxylate of D170 is more
likely to protonate, losing its ionic interaction with the nitrogen
of DGJ, leading to weaker binding. In our model, the protonation
state of the D170 carboxylate affects the affinity of a-GAL
for DGJ, and removal of the carboxylate in the D170A a-GAL
variant leads to much weaker binding to DGJ. Our experiments
do not support an alternative model where protonation of the
nitrogen in DGJ leads to weaker binding of the PC (Fantur
et al., 2010).
In conclusion, we have made the following observations about
the interaction of a-GAL and PCs. First, DGJ binds to the WT
a-GAL and stabilizes the enzyme, as shown by the CD, fluores-
cence, and proteolysis experiments. Second, in all the biochem-
ical experiments, the protective effect of DGJ is greater at neutralFigure 4. Crystal Structures of Human a-GAL
Bound to Pharmacological Chaperones
(A–C) sA-Weighted 2Fo-Fc electron density maps of DGJ-
and galactose-soaked crystals of WT human a-GAL
(A and B) and the D170A mutant a-GAL with DGJ bound
(C). All maps are contoured at 1.8 swith the ligand density
colored red for clarity.
(D) A superposition of (A) and (B) highlights the key inter-




Pharmacological Chaperone MechanismpH than at pH 4.5. Third, galactose is capable of PC activity
but requires 10,000- to 100,000-fold higher concentrations
than DGJ, consistent with the differences in Ki measured in
enzymatic assays. Fourth, crystal structures show that the PCs
bind exclusively to the active site, and the protective effect of
the chaperones derives from specific interactions with active
site residues. As a counter example, glucose binds weakly to
a-GAL away from the active site (Guce et al., 2010) but does
not show the same chaperoning effect as DGJ or galactose.
Fifth, the enhanced potency of DGJ results from interactions
with the D170 carboxylate. When the carboxylate is removed
in the D170A variant, DGJ chaperones no better than galactose.
We have identified the key atomic interaction responsible for the
increased potency of DGJ. These results can be generalized to
the entire family of active-site-specific chaperones, allowing for
development of improved chaperones.
SIGNIFICANCE
Using a pharmacological chaperone to treat a protein
folding disease presents a molecular paradox: to increase
the activity of the enzyme, a competitive inhibitor of the
enzyme is used. We probe the molecular mechanism of the
paradox using biochemical and biophysical approaches on
human a-GAL, including enzyme kinetics, chemical denatur-
ation monitored by fluorescence, thermal denaturation
monitored by circular dichroism, protease susceptibility,
and X-ray crystallography. Our studies show that 1-deoxy-
galactonojirimycin (DGJ), which is only two functional
groups different from galactose, is a 400,000-fold better
binder. We hypothesize that a single ionic interaction is
responsible for the higher potency of DGJ. We test the
hypothesis using a D170A mutant a-GAL lacking the ionic
interaction, which loses the high potency of DGJ.We explore
the pH dependence of pharmacological chaperone binding,
as the chaperonesmust dissociate from a-GAL in the low pH
of the lysosome. In this article, we refute one proposed
mechanism of action (that protonation of the small molecule
leads to weaker binding in the lysosome) and propose that
protonation of the catalytic nucleophile D170 causesweaker
DGJ binding at low pH.
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